Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Hexima Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Geoffrey Kempler

İcra Kurulu Başkanı

AU$109.8k

Toplam tazminat

CEO maaş yüzdesi	38.8%
CEO görev süresi	1.1yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.9yrs
Yönetim Kurulu ortalama görev süresi	3.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Geoffrey Kempler'un ücretlendirmesi Hexima'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	AU$110k	AU$43k	-AU$934k

Tazminat ve Piyasa: Geoffrey 'nin toplam tazminatı ($USD 75.66K ), Australian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 313.13K ).

Tazminat ve Kazançlar: Geoffrey şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Geoffrey Kempler (69 yo)

1.1yrs

Görev süresi

AU$109,813

Tazminat

Mr. Geoffrey Paul Kempler, B.Sc. Grad. Dipp. App. Soc.Psych, serves as Chairman and Managing Director of Hexima Ltd since September 05, 2023. Mr. Kempler is Chairman of AusBiotech. He Co-Founded Alterity...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Geoffrey Kempler	MD & Chairman	1.1yrs	AU$109.81k	Veri yok
Helen Molloy	Financial Controller	no data	AU$224.24k	Veri yok
Marilyn Anderson	Chief Science Officer	15.3yrs	AU$48.63k	1.44% A$ 40.9k
Neil Forrester	Vice President of Business Development	no data	Veri yok	Veri yok
Nancy Sacco	Chief Development Officer	2.8yrs	AU$175.25k	Veri yok
Leanne Ralph	Company Secretary	3yrs	Veri yok	Veri yok

2.9yrs

Ortalama Görev Süresi

Deneyimli Yönetim: HXL 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.9 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Geoffrey Kempler	MD & Chairman	1.1yrs	AU$109.81k	Veri yok
Richard Scher	Member of the Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Tracey Vlahovic	Member of the Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Phoebe Rich	Member of the Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Warren Joseph	Member of the Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Justin Yap	Non-Executive Director	6.3yrs	Veri yok	Veri yok
Mark Lebwohl	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Boni Elewski	Member of the Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Peter Foley	Member of the Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Shinichi Watanabe	Member of the Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Robert Rosen	Member of the Scientific Advisory Board	3.6yrs	Veri yok	Veri yok
Shari Lipner	Member of the Scientific Advisory Board	2.8yrs	Veri yok	Veri yok

3.6yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: HXL 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.6 yıldır).

Hexima Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

No independent directors

Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director

Hexima Limited, Annual General Meeting, Nov 28, 2023

Hexima Limited Appoints Phillip Hains as A Non-Executive Director

Insider recently bought AU$155k worth of stock

Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director

Recent updates

Hexima Limited has filed a Follow-on Equity Offering in the amount of AUD 7.5 million.

Real Thing Entertainment agreed to acquire Hexima Limited (ASX:HXL) in a reverse merger transaction for AUD 8.1 million.

No independent directors

Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director

Hexima Limited, Annual General Meeting, Nov 28, 2023

Hexima Limited Appoints Phillip Hains as A Non-Executive Director

Full year 2023 earnings released: AU$0.011 loss per share (vs AU$0.066 loss in FY 2022)

New minor risk - Financial data availability

Insider recently bought AU$155k worth of stock

Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.029 loss in 1H 2022)

Nicole Van Der Weerden to Step Down as CEO of Hexima Limited

Hexima Limited, Annual General Meeting, Jan 31, 2023

Hexima Limited Announces Board Changes

Less than half of directors are independent

Hexima Limited, Annual General Meeting, Nov 16, 2022

Full year 2022 earnings released: AU$0.066 loss per share (vs AU$0.061 loss in FY 2021)

Hexima Limited Announces Management Changes

Hexima Limited Announces Phase II Results of Pezadeftide

Hexima Limited Announces Preliminary Results of Phase II Clinical Study of Pezadeftide

Less than half of directors are independent

Is Hexima (ASX:HXL) In A Good Position To Invest In Growth?

Here's Why We're A Bit Worried About Hexima's (ASX:HXL) Cash Burn Situation

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Director Jason Nunn has joined 5th company board

Full year 2021 earnings released: AU$0.061 loss per share (vs AU$0.028 loss in FY 2020)

Hexima Limited Extends Its Patent Protection for Pezadeftide

Hexima Limited to Present Clinical Data from its Phase I/IIa Clinical Trial of HXP 124 for the Treatment of Onychomycosis at American Podiatric Medical Association Annual Conference

Read This Before Selling Hexima Limited (ASX:HXL) Shares

Hexima Limited Updates Timeline to Phase 2B Results

Hexima Limited has completed an IPO in the amount of AUD 3.280771 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi